Skip to main content

Table 2 Hematological toxicity criteria for irinotecan dose adjustment

From: Does a ketogenic diet as an adjuvant therapy for drug treatment enhance chemotherapy sensitivity and reduce target lesions in patients with locally recurrent or metastatic Her-2-negative breast cancer? Study protocol for a randomized controlled trial

Minimal value

Dose in the next cycle

Neutrophil count (×  109/L)

Platelet count (×  109/L)

≥ 0.5

… and ≥ 50

No change

<  0.5 or ≥ 0.5 accompanied by fever and lack of granulocytes

… or < 50

Irinotecan dose decreased by 20%

Back to article page

Trials

ISSN: 1745-6215